MBX Biosciences said Q2 2026 results were driven by pipeline progress, underscoring how closely its financial update is tied to R&D execution. The company is al

MBX Biosciences said Q2 2026 results were driven by pipeline progress, underscoring how closely its financial update is tied to R&D execution. The company is also expanding hiring to support precision peptide therapies for obesity and hypoparathyroidism.